AMETEK, Inc. (AME) Stock Price Today
Aura AI Summary
Key Stats
- $51.11BMarket Cap
- 1,810,363Volume
- IndustrialsSector
- $258.5252W High
- $195.0252W Low
- 74 DaysTypical Hold Time
- $57.12BEnterprise Value
- 0.61%Div Yield
- -Trading Activity
Track AMETEK, Inc. (AME) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, AMETEK, Inc. has traded between a low of $195.02 and a high of $258.52, highlighting its annual price range. Buy and sell AMETEK, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Most Recent News
Home Depot and Lowe's see declining sales amid high mortgage rates and weak housing market.
Home Depot and Lowe's reported declines in comparable transactions in Q3 2026 due to a sluggish housing market and rising mortgage rates now above 7%. This has led to fewer home sales and softer demand for home improvement projects, as consumers dela...

Tesla's Cybercab launch signals robotaxi growth in 2027, urging caution on a SpaceX merger before success.
Tesla has started selling Cybercabs, priced at $29,990 with a $299 monthly subscription, but their current use is limited to specific areas and lacks manual controls. This launch is mainly promotional, highlighting Tesla's focus on becoming a transpo...

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.
Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 d...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.